Peripheral arterial disease (PAD) affects 8 million Americans and results in pain, gangrene, and limb amputation. Current treatments are limited. We previously demonstrated that human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) can improve blood perfusion in animal models of PAD; however, their angiogenic potential remains limited. While many single-variable (univariate) matrix studies have emphasized the importance of matrix-based cues for endothelial cell survival and function, few have focused on understanding these processes in multivariate materials, which mimic the complexity of the natural extracellular matrix (ECM). To address this limitation, we develop a combinatorial family of engineered ECMs (eECMs) with independently tunable biochemical and biomechanical cues, including stiffness and stress relaxation rate for high-throughput, matrix array studies of iPSC-EC survival and angiogenic potential.
In Aim 1, we test the hypothesis that multivariate analysis will lead to the identification of optimal eECMs that enhance the regenerative capacity of iPSC-ECs and uncover previously unknown cross-talk between distinct matrix cues. Preliminary work using matrix arrays of naturally derived ECM components identified several previously unknown synergistic and antagonistic interactions between matrix cues. We build on these exciting results by creating a new array platform for combinatorial screening of modular eECMs designed for clinical translation. The eECM is an injectable hydrogel composed of recombinantly engineered matrix-mimetic proteins and polyethylene glycol crosslinked using dynamic covalent chemistry (DCC). Matrix biochemical cues are modified through protein engineering, while gel stiffness and stress relaxation rate are independently tuned through the number and kinetics of crosslinks, respectively. An in vitro array of 279 unique, combinatorial eECMs will be screened for iPSC-EC viability, phenotype, and function. Multi-factorial mathematical analyses will rank the relative importance of each eECM variable, as well as interaction effects that lead to synergistic enhancement. Results will be validated using conventional tissue culture assays.
In Aim 2, we test the hypothesis that iPSC-ECs on pro-angiogenic, multivariate eECMs will have a distinctive, mechanistic signature. Integrin-mediated signaling pathways will be quantitatively assessed to correlate observed angiogenic responses to mechanistic pathways, and confirmed through gain- and loss- of-function studies. RNA sequencing will reveal new pathways and driver genes mediating the process, ultimately demonstrating a molecular signature characteristic of pro-angiogenic effects of multivariate eECMs.
In Aim 3, we perform in vivo validation of the therapeutic potential of iPSC-ECs within the optimal eECM in a murine model of PAD. Controls include cells seeded in eECM with univariate cell-binding ligands or non- optimal mechanical properties, or cells delivered in saline. Cell survival will be tracked by bioluminescence imaging; laser Doppler spectroscopy and histology will determine vascular regeneration.

Public Health Relevance

Transplantation of human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) is a promising approach to treating peripheral arterial disease (PAD); however, the angiogenic potential of this cell type remains limited. This proposal aims to improve the clinical efficacy of iPSC-EC transplants through the design of a novel combinatorial family of engineered extracellular matrices (eECMs) with independently tunable biochemical and biomechanical cues to allow identification of optimal eECMs that promote iPSC-EC angiogenic potential. An in vitro array of 279 unique, combinatorial eECMs will be screened for enhancement of iPSC-EC viability, phenotype, and function, and optimal eECMs will be validated in a preclinical animal model of PAD.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL142718-01
Application #
9576990
Study Section
Biomaterials and Biointerfaces Study Section (BMBI)
Program Officer
Lundberg, Martha
Project Start
2018-07-01
Project End
2022-03-31
Budget Start
2018-07-01
Budget End
2019-03-31
Support Year
1
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Stanford University
Department
Surgery
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94304
Nakayama, Karina H; Alcazar, Cynthia; Yang, Guang et al. (2018) Rehabilitative exercise and spatially patterned nanofibrillar scaffolds enhance vascularization and innervation following volumetric muscle loss. NPJ Regen Med 3:16
Zamani, Maedeh; Karaca, Esra; Huang, Ngan F (2018) Multicellular Interactions in 3D Engineered Myocardial Tissue. Front Cardiovasc Med 5:147